• Steadily growing plasma donations in Egypt will become lifesaving treatments for Egyptian patients, including immunoglobulins, albumin and blood-clotting factors
• New donation centers are opening and manufacturing facilities are being built as part of the world’s first integrated plasma-supply platform that Grifols and Egypt’s National Service Projects Organization are establishing to achieve Egyptian and regional self-sufficiency in plasma-derived medicines
• Grifols global leadership in creating innovative alliances between the plasma industry and the public sector is helping ensure domestic plasma security

National Service Projects Organization (NSPO) and Grifols, one of the world’s leading producers of plasma-derived medicines with more than a 110-year track record of contributing to the health and well-being of people around the world,  have announced that the first shipment of Egyptian plasma has arrived in Spain, where it will be manufactured into lifesaving plasma medicines to treat patients in Egypt.

Increasing amounts of Egyptian plasma will arrive in Barcelona regularly as part of the strategic agreement that NSPO signed with Grifols in November 2020 which resulted in establishing the joint venture "Grifols Egypt for Plasma Derivatives." The joint venture is currently building the world’s very first integrated plasma infrastructure, including donation centers throughout Egypt as well as plasma fractionation and purification plants, in addition to testing and warehouse operations, in the New Administrative Capital’s medical city.

Under the terms of the game-changing alliance, Grifols’ manufacturing installations in Spain will produce plasma medicines for export back to Egypt after going through the fractionation process. This will be an ongoing until the end of 2025, when the in-country manufacturing site is expected to be operational.

In 2022, thousands of qualified Egyptian donors contributed to plasma donations, which will yield tens of thousands of grams of plasma medicines including immunoglobulin (Ig) and albumin in addition to blood-clotting factors. Those essential medicines are used to treat many rare, chronic, and at times life-threatening conditions such as immunodeficiencies, cardiopulmonary issues,  emergency medicine to treat shock and severe burns, as well as bleeding disorders.

“Today, and thanks to the generous donations of Egyptians, Egypt has taken a huge step forward in its vision to be a regional leader in plasma medicines and healthcare,” said Dr. Magdy Amin, CEO of Grifols Egypt.

“The manufacturing of plasma medicines for Egyptian patients with Egyptian plasma is a reality and a milestone in establishing an end-to-end plasma supply hub for Africa and the Middle East, said Víctor Grifols Deu, co-CEO of Grifols.